{"id":71150,"date":"2022-02-16T10:27:49","date_gmt":"2022-02-16T09:27:49","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/splicebio-raises-eur-50m-in-oversubscribed-series-a\/"},"modified":"2023-09-12T12:48:08","modified_gmt":"2023-09-12T10:48:08","slug":"splicebio-raises-eur-50m-in-oversubscribed-series-a","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/splicebio-raises-eur-50m-in-oversubscribed-series-a\/","title":{"rendered":"SpliceBio raises \u20ac50 million in oversubscribed Series A financing"},"content":{"rendered":"<p><strong><a href=\"https:\/\/www.pcb.ub.edu\/en\/empresa\/splicebio\/\" target=\"_blank\" rel=\"noopener\">SpliceBio<\/a>, a biotechnology company exploiting protein splicing to develop next generation gene therapies, today announced the completion of an oversubscribed \u20ac50 million series A financing. Proceeds will be used to advance <a href=\"https:\/\/splice.bio\/protein-splicing\/\" target=\"_blank\" rel=\"noopener\">Protein Splicing<\/a> and its lead program in Stargardt disease into the clinic, and also expand pipeline to other currently untreatable genetic diseases.<\/strong><\/p>\n<p>The financing was co-led by\u00a0<a href=\"http:\/\/www.ucbventures.com\/\" target=\"_blank\" rel=\"noopener\">UCB Ventures<\/a>\u00a0and existing shareholder\u00a0<a href=\"http:\/\/www.ysioscapital.com\/\" target=\"_blank\" rel=\"noopener\">Ysios Capital<\/a>\u00a0and joined by new investors<a href=\"http:\/\/www.nea.com\/\" target=\"_blank\" rel=\"noopener\">\u00a0New Enterprise Associates (NEA)<\/a>,\u00a0<a href=\"http:\/\/www.gildehealthcare.com\/\" target=\"_blank\" rel=\"noopener\">Gilde Healthcare<\/a>,\u00a0<a href=\"http:\/\/www.nvfund.com\/\" target=\"_blank\" rel=\"noopener\">Novartis Venture Fund<\/a>, and existing shareholder <a href=\"http:\/\/www.asabys.com\/\" target=\"_blank\" rel=\"noopener\">Asabys Partners<\/a>. The Company was seeded in 2020 by Ysios Capital and Asabys Partners.<\/p>\n<p>Adeno-associated viruses (AAV) are the gene therapy vector of choice for the treatment of genetic diseases. However, their small packaging capacity is a major challenge for the development of novel gene therapies. SpliceBio\u2019s Protein Splicing platform aims to address this major limitation to enable the efficient delivery of large genes using AAV vectors. The platform is based on technology developed in the <a href=\"https:\/\/muir.princeton.edu\/\" target=\"_blank\" rel=\"noopener\">Muir Lab<\/a> at Princeton University after more than 20 years of pioneering intein and protein engineering research. In this novel approach, engineered inteins catalyse highly efficient protein trans-splicing to reconstitute the desired full-length therapeutic protein in vivo.<\/p>\n<p>The proceeds from the financing, the largest Series A round for a Spanish biotech company, will enable SpliceBio to build a pipeline of Protein Splicing gene therapy programs, while advancing the lead program in Stargardt disease to the clinic. Stargardt disease is the most common form of juvenile macular dystrophy, affecting more than 80,000 people in the US and EU. The disease is caused by a loss of function mutation in the ABCA4 gene, which at 6.8 kb is too large for single AAV vectors. The Company will focus its efforts on ophthalmology as well as other disease areas of significant unmet patient need. The platform has been validated in several other organs beyond the retina.<\/p>\n<p><strong>Miquel Vila-Perello\u0301, <\/strong>PhD, co-founder and Chief Executive Officer of SpliceBio, said<strong>:<\/strong>\u00a0\u201cWe are very pleased to attract this outstanding syndicate of institutional and corporate investors which validates our approach to developing next generation gene therapies. I am excited to lead an exceptional team as we continue to build our platform and advance our pipeline of gene therapy programs into the clinic.\u201d<\/p>\n<p>Following the closing of the financing, the Board of SpliceBio chaired by <strong>Jean Philippe Combal<\/strong> will include:<strong> Erica Whittaker<\/strong>, UCB Ventures; <strong>Joe\u0308l Jean-Mairet<\/strong>, Ysios Capital; <strong>Ed Mathers<\/strong>, NEA; <strong>Arthur Franken<\/strong>, Gilde Healthcare; <strong>Beat Steffen<\/strong>, Novartis Venture Fund; and <strong>Miquel Vila- Perello\u0301<\/strong>, CEO.<\/p>\n<p><strong>Erica Whittaker<\/strong>, vice-president and Head of UCB Ventures, stated<strong>:<\/strong>\u00a0\u201cWe are delighted to support SpliceBio in the development of its innovative platform to create treatments for patients suffering from genetic diseases not currently addressable by existing gene therapy approaches.\u201d<\/p>\n<p><strong>Joe\u0308l Jean-Mairet<\/strong>, managing partner at Ysios Capital, added:\u00a0\u201cWe are proud to have been involved with the Company since its early days and are very impressed with the progress achieved to date. SpliceBio\u2019s platform represents an unprecedented opportunity to expand the universe of diseases that can be addressed with gene therapy. This financing is also a testament to the growing potential of the biotech hub in Barcelona.\u201d<\/p>\n<div class=\"page\" title=\"Page 2\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Ed Mathers<\/strong>, general partner at NEA, commented: \u201cWe are very pleased to back this team, building on the founders\u2019 early-stage research at Princeton\u2019s Muir Laboratory to develop SpliceBio into a world leading gene therapy player. We believe SpliceBio\u2019s innovative approach to maximizing the capacity of AAV vectors has the potential to make a meaningful impact in the delivery of much-needed gene therapies, and we look forward to supporting the Company through its next stages of growth.\u201d<\/p>\n<p><strong>\u00bb More information: <a href=\"https:\/\/splice.bio\/splicebio-raises-eur-50m-in-oversubscribed-series-a-financing-to-advance-protein-splicing-platform-and-expand-gene-therapy-pipeline\/\" target=\"_blank\" rel=\"noopener\">SpliceBio website [+]<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>SpliceBio, a biotechnology company exploiting protein splicing to develop next generation gene therapies, today announced the completion of an oversubscribed \u20ac50 million series A financing. Proceeds will be used to&#8230;<\/p>\n","protected":false},"author":4,"featured_media":71142,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[43],"tags":[],"class_list":["post-71150","post","type-post","status-publish","format-standard","has-post-thumbnail","category-investment"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SpliceBio raises \u20ac50 million in oversubscribed Series A financing - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/en\/splicebio-raises-eur-50m-in-oversubscribed-series-a\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SpliceBio raises \u20ac50 million in oversubscribed Series A financing - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"SpliceBio, a biotechnology company exploiting protein splicing to develop next generation gene therapies, today announced the completion of an oversubscribed \u20ac50 million series A financing. Proceeds will be used to...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/en\/splicebio-raises-eur-50m-in-oversubscribed-series-a\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-16T09:27:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-12T10:48:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/02\/Splice-management-teamwebpcb.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"340\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Azucena Berea\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Azucena Berea\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/splicebio-raises-eur-50m-in-oversubscribed-series-a\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/splicebio-raises-eur-50m-in-oversubscribed-series-a\\\/\"},\"author\":{\"name\":\"Azucena Berea\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/810a86a39effe6bf90f9ab918ca43239\"},\"headline\":\"SpliceBio raises \u20ac50 million in oversubscribed Series A financing\",\"datePublished\":\"2022-02-16T09:27:49+00:00\",\"dateModified\":\"2023-09-12T10:48:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/splicebio-raises-eur-50m-in-oversubscribed-series-a\\\/\"},\"wordCount\":609,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/splicebio-raises-eur-50m-in-oversubscribed-series-a\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/Splice-management-teamwebpcb.jpg\",\"articleSection\":[\"INVESTMENT\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/splicebio-raises-eur-50m-in-oversubscribed-series-a\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/splicebio-raises-eur-50m-in-oversubscribed-series-a\\\/\",\"name\":\"SpliceBio raises \u20ac50 million in oversubscribed Series A financing - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/splicebio-raises-eur-50m-in-oversubscribed-series-a\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/splicebio-raises-eur-50m-in-oversubscribed-series-a\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/Splice-management-teamwebpcb.jpg\",\"datePublished\":\"2022-02-16T09:27:49+00:00\",\"dateModified\":\"2023-09-12T10:48:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/810a86a39effe6bf90f9ab918ca43239\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/splicebio-raises-eur-50m-in-oversubscribed-series-a\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/splicebio-raises-eur-50m-in-oversubscribed-series-a\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/splicebio-raises-eur-50m-in-oversubscribed-series-a\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/Splice-management-teamwebpcb.jpg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/Splice-management-teamwebpcb.jpg\",\"width\":900,\"height\":340},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/splicebio-raises-eur-50m-in-oversubscribed-series-a\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SpliceBio raises \u20ac50 million in oversubscribed Series A financing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/810a86a39effe6bf90f9ab918ca43239\",\"name\":\"Azucena Berea\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/32577545a82a87a5c7e06fb02f02362edb2f379afdb4c8b5783d81635141181f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/32577545a82a87a5c7e06fb02f02362edb2f379afdb4c8b5783d81635141181f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/32577545a82a87a5c7e06fb02f02362edb2f379afdb4c8b5783d81635141181f?s=96&d=mm&r=g\",\"caption\":\"Azucena Berea\"},\"sameAs\":[\"https:\\\/\\\/www.pcb.ub.edu\"],\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/aberea\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SpliceBio raises \u20ac50 million in oversubscribed Series A financing - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/en\/splicebio-raises-eur-50m-in-oversubscribed-series-a\/","og_locale":"en_US","og_type":"article","og_title":"SpliceBio raises \u20ac50 million in oversubscribed Series A financing - Parc Cient\u00edfic de Barcelona","og_description":"SpliceBio, a biotechnology company exploiting protein splicing to develop next generation gene therapies, today announced the completion of an oversubscribed \u20ac50 million series A financing. Proceeds will be used to...","og_url":"https:\/\/www.pcb.ub.edu\/en\/splicebio-raises-eur-50m-in-oversubscribed-series-a\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2022-02-16T09:27:49+00:00","article_modified_time":"2023-09-12T10:48:08+00:00","og_image":[{"width":900,"height":340,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/02\/Splice-management-teamwebpcb.jpg","type":"image\/jpeg"}],"author":"Azucena Berea","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Azucena Berea","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/en\/splicebio-raises-eur-50m-in-oversubscribed-series-a\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/en\/splicebio-raises-eur-50m-in-oversubscribed-series-a\/"},"author":{"name":"Azucena Berea","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/810a86a39effe6bf90f9ab918ca43239"},"headline":"SpliceBio raises \u20ac50 million in oversubscribed Series A financing","datePublished":"2022-02-16T09:27:49+00:00","dateModified":"2023-09-12T10:48:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/splicebio-raises-eur-50m-in-oversubscribed-series-a\/"},"wordCount":609,"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/splicebio-raises-eur-50m-in-oversubscribed-series-a\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/02\/Splice-management-teamwebpcb.jpg","articleSection":["INVESTMENT"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/en\/splicebio-raises-eur-50m-in-oversubscribed-series-a\/","url":"https:\/\/www.pcb.ub.edu\/en\/splicebio-raises-eur-50m-in-oversubscribed-series-a\/","name":"SpliceBio raises \u20ac50 million in oversubscribed Series A financing - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/splicebio-raises-eur-50m-in-oversubscribed-series-a\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/splicebio-raises-eur-50m-in-oversubscribed-series-a\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/02\/Splice-management-teamwebpcb.jpg","datePublished":"2022-02-16T09:27:49+00:00","dateModified":"2023-09-12T10:48:08+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/810a86a39effe6bf90f9ab918ca43239"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/en\/splicebio-raises-eur-50m-in-oversubscribed-series-a\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/en\/splicebio-raises-eur-50m-in-oversubscribed-series-a\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/en\/splicebio-raises-eur-50m-in-oversubscribed-series-a\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/02\/Splice-management-teamwebpcb.jpg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/02\/Splice-management-teamwebpcb.jpg","width":900,"height":340},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/en\/splicebio-raises-eur-50m-in-oversubscribed-series-a\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"SpliceBio raises \u20ac50 million in oversubscribed Series A financing"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/810a86a39effe6bf90f9ab918ca43239","name":"Azucena Berea","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/32577545a82a87a5c7e06fb02f02362edb2f379afdb4c8b5783d81635141181f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/32577545a82a87a5c7e06fb02f02362edb2f379afdb4c8b5783d81635141181f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/32577545a82a87a5c7e06fb02f02362edb2f379afdb4c8b5783d81635141181f?s=96&d=mm&r=g","caption":"Azucena Berea"},"sameAs":["https:\/\/www.pcb.ub.edu"],"url":"https:\/\/www.pcb.ub.edu\/en\/author\/aberea\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/71150","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=71150"}],"version-history":[{"count":10,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/71150\/revisions"}],"predecessor-version":[{"id":87750,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/71150\/revisions\/87750"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/71142"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=71150"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=71150"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=71150"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}